MAI Capital Management Increases Position in AbbVie Inc. $ABBV

MAI Capital Management increased its holdings in AbbVie Inc. (NYSE:ABBV) by 1.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 546,284 shares of the company’s stock after acquiring an additional 6,850 shares during the quarter. AbbVie comprises approximately 0.8% of MAI Capital Management’s investment portfolio, making the stock its 27th largest holding. MAI Capital Management’s holdings in AbbVie were worth $126,487,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Diversified Trust Co boosted its position in shares of AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after buying an additional 10,891 shares during the period. Permanent Capital Management LP acquired a new stake in shares of AbbVie during the third quarter valued at approximately $720,000. Railway Pension Investments Ltd boosted its stake in shares of AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after buying an additional 211,800 shares during the period. World Investment Advisors grew its stake in shares of AbbVie by 9.4% in the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after buying an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co increased its holdings in shares of AbbVie by 93.4% during the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after acquiring an additional 15,502 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $228.44 on Wednesday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a 50-day simple moving average of $224.17 and a 200 day simple moving average of $222.67. The company has a market capitalization of $403.92 billion, a P/E ratio of 96.80, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of research reports. Scotiabank began coverage on AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Piper Sandler raised their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Royal Bank Of Canada set a $260.00 price objective on AbbVie and gave the stock an “outperform” rating in a research note on Tuesday. UBS Group dropped their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Finally, Evercore decreased their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Announced a $380 million investment to build two new active pharmaceutical ingredient (API) plants at its North Chicago campus to support next‑generation neuroscience and obesity medicines; construction starts spring 2026 and facilities are expected online by 2029 — boosts capacity, onshoring and long‑term production control. AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
• Positive Sentiment: FDA approved the VENCLEXTA (venetoclax) + acalabrutinib combination as a first‑line, all‑oral fixed‑duration regimen for previously untreated CLL — a label expansion that can meaningfully enlarge addressable market and near‑term revenue potential. FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and $275 price target, calling out upside from operating‑leverage and growth potential — an influential analyst endorsement that may support the stock. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential
• Positive Sentiment: Coverage pieces highlighting AbbVie’s high dividend yield and steady payout profile continue to attract income investors, supporting demand for the shares from yield‑focused buyers. This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
• Neutral Sentiment: Company to present at the TD Cowen Healthcare Conference on March 3 — standard investor access that offers a near‑term catalyst for management commentary but no immediate guarantee of new guidance. AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in Bipolar I disorder — a data milestone that reduces uncertainty around real‑world use but is unlikely to move revenue materially in the near term. AbbVie’s Real‑World Vraylar Study in Bipolar I Disorder Reaches Completion
• Neutral Sentiment: Early‑stage progress: AbbVie launched a Phase 1 trial for ABBV‑8736 to compare injection routes — positive for pipeline momentum but inherently early and higher risk. AbbVie Advances ABBV-8736 With New Trial Comparing Injection Routes
• Neutral Sentiment: Coverage and fair‑value tweaks from some outlets modestly lifted model targets (small upward adjustments) — indicates analysts are refining views rather than issuing large directional revisions. How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative
• Negative Sentiment: Analysts and articles flag increasing competition (and lingering execution risk) in immunology and other franchises; that pressure, plus the need to replace legacy revenue over time, is a structural headwind for multiples. Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
• Negative Sentiment: Big capex spend has long‑term benefits but increases near‑term cash deployment; investors concerned about execution/timing (projects complete by 2029) may be cautious in the near term. AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.